Industry Bulletins | December 11, 2019
Otsuka Announces Retirement Of President & Chief Executive Officer
Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) announced that effective January 1, 2020, William H. Carson, M.D., president and chief executive officer (CEO) will retire from the company’s operational leadership. Dr. Carson will transition to Chairman of the OPDC Board of Directors, as well as spearhead Otsuka philanthropic initiatives to be announced in 2020.
Dr. Carson joined Otsuka in 2002 as a board-certified psychiatrist. During his tenure, Dr. Carson has helped OPDC realize the promise of various compounds, leading the way from clinical trials to commercialization of products that include SAMSCA® (tolvaptan), ABILIFY MAINTENA® (aripiprazole), REXULTI® (brexpiprazole . . .